Humana Inc (HUM)

Sep 27, 2026

UnitedHealth (UNH) stock is up 14% in 2026, reaching $376.59 after appointing a new chief administrative officer and elevating its chief commercial officer. The company's Medicaid and Optum Health segments are projected to improve significantly in 2027, with Medicaid margins expected to recover and Optum Health's margins set to expand. Despite potential risks from Medicare Advantage audits and Star ratings, analysts anticipate strong third-quarter adjusted EPS, suggesting that holding or adding to positions before the October 13 earnings report may be favorable.

Sep 25, 2026

Humana Inc. shares surged by 6% after Barclays upgraded the health insurer to "overweight" from "equal-weight," anticipating a rebound in Medicare Star ratings. Analyst Andrew Mok cited increased confidence in Humana's ability to achieve "bonus status" for several contracts, particularly the critical H5216 contract which significantly impacts the company's long-term EPS target. Barclays raised Humana's price target to $515 from $407, expecting the star ratings release around October 8.

Sep 25, 2026

Humana Inc. shares surged 6% following Barclays' upgrade of the health insurer to "overweight" from "equal-weight." The upgrade is based on Barclays' increased confidence in Humana's potential for improved Medicare Star ratings, particularly the critical H5216 contract. Analyst Andrew Mok raised the price target to $515 from $407, citing a stronger position for Humana in the upcoming ratings cycle.

Sep 25, 2026

Humana's stock surged 7% after Barclays upgraded the company to Overweight and raised its price target to $515, extending an already strong year-to-date performance. This rally is company-specific, as other managed care stocks like UnitedHealth saw only modest gains, suggesting the move is driven by analyst sentiment rather than broad sector trends. Investors are now watching for other research firms to follow Barclays' lead, as the sustained gain hinges on wider acceptance of this bullish view before Humana's upcoming quarterly earnings.

Sep 24, 2026

UnitedHealth (UNH) is facing significant margin pressure in its commercial segment due to issues like arbitration abuse under the No Surprises Act and increased provider coding intensity, which a Blue Cross Blue Shield Association study linked to AI tools used by providers, costing insurers $942 million industry-wide. Management has pushed back commercial margin recovery targets to beyond 2027. UnitedHealth is responding by leveraging its Optum Insight segment, which provides AI-driven coding accuracy and prior authorization tools, to counteract these billing challenges, with its operating margin recently swinging from a loss to a record 25.4%.

Sep 23, 2026

State Street Corp increased its stake in Humana Inc. by 0.1% in the second quarter, acquiring an additional 4,080 shares and bringing its total holdings to 5.46 million shares, representing 4.54% of the company. Institutional investors and hedge funds now collectively own 92.38% of Humana. The company reported strong Q2 earnings with EPS of $7.61 and revenue of $40.89 billion, exceeding analyst expectations, and declared a quarterly dividend of $0.885 per share.

Sep 22, 2026

Thirty brokerages have assigned Humana Inc. (NYSE:HUM) a consensus "Hold" rating, with an average 12-month price target of $403.91. The company recently reported strong quarterly earnings of $7.61 per share, exceeding estimates, and revenue grew 26.2% year over year to $40.89 billion. Institutional investors have significantly increased their stakes in Humana, with 92.38% of the company's stock owned by institutions.

Sep 21, 2026

Nykredit A S has made a new investment of $12.46 million in Humana Inc. (NYSE:HUM) by purchasing 31,361 shares during the second quarter. This move is part of broader institutional interest, with other major investors like BlackRock Inc. and Pzena Investment Management LLC also adjusting their stakes in Humana. The article also details recent analyst ratings, Humana's price performance, earnings, and dividend announcements.

Sep 19, 2026

Wall Street Zen has upgraded Humana (NYSE:HUM) from a "Hold" to a "Buy" rating, despite the broader analyst consensus remaining "Hold" with a price target of $403.91. Humana's shares opened at $385.81, near its 52-week high, and the company recently exceeded quarterly earnings expectations with $7.61 adjusted EPS and $40.89 billion in revenue. Institutional investors hold a significant portion of the company's stock, with 92.38% ownership.

Sep 17, 2026

Carelon, a segment of Elevance Health (ELV), is becoming a crucial driver for the company's long-term growth by expanding beyond traditional health insurance into integrated care delivery, pharmacy, and care management. Despite a first-quarter operating gain decline due to membership issues and investments, its capabilities in improving clinical outcomes and operational efficiency position it for future success. This growth complements Elevance Health's overall financial momentum and competitive standing against rivals like UnitedHealth Group and Humana, even as its stock performance and valuation show mixed signals.

Sep 17, 2026

Centene (CNC) is showing signs of profitability recovery in Q2 2026, driven by better medical cost trends and strong execution, with adjusted EPS increasing significantly year-over-year. Despite this, membership pressure, particularly in Medicaid, remains a challenge. The company is working to offset these losses through improved Medicaid rates, cost reduction initiatives, and profitability in Marketplace and Medicare segments, while competitors like UnitedHealth and Humana are also navigating similar market dynamics.

Sep 17, 2026

CVS Health's Aetna health insurance unit announced it will simplify the prior authorization process for cancer treatments starting in 2027. Instead of multiple approvals for various components of care, providers will submit a single preapproval based on documentation showing the patient is receiving cancer treatment. This change aims to reduce administrative burden for healthcare providers and will be rolled out across private, Medicare Advantage, and some Medicaid plans.

Sep 17, 2026

Bank of America Corp DE acquired a significant new stake in Humana Inc. during the second quarter, purchasing 703,615 shares valued at approximately $279.49 million, representing about 0.59% of the company. Humana reported strong quarterly earnings, beating analyst estimates with $7.61 EPS and revenue of $40.89 billion, a 26.2% year-over-year increase. Despite a recent 3.1% decline in its share price to $384.46, analysts have a "Hold" consensus rating with a target price of $403.91, and the company also declared a quarterly dividend of $0.885 per share.

Sep 16, 2026

Baird Financial Group Inc. increased its stake in Humana Inc. by 58.2% in the second quarter, acquiring an additional 4,129 shares to bring its total holdings to 11,228 shares valued at $4.46 million. Humana has an average "Hold" rating from analysts with a target price of $403.91, and reported strong quarterly earnings of $7.61 per share and $40.89 billion in revenue, exceeding expectations. The company also declared a quarterly dividend of $0.885 per share.

Sep 15, 2026

Healthcare Services Group (NASDAQ:HCSG) stock recently crossed above its 200-day moving average, trading at $22.04 with a 200-day average of $21.63. Analysts have a "Moderate Buy" consensus rating and a $26.50 price target, following the company's beat on quarterly earnings with $0.32 EPS. Despite significant institutional ownership, the COO recently sold 15,598 shares, signaling a reduction in insider holdings.

Sep 14, 2026

Travelers (NYSE:TRV) has seen a significant market run, leading its valuation to now sit above its estimated fair value. While the company demonstrates strong underwriting and diversified operations, concerns are rising around whether its operational strengths can sustain this elevated valuation, especially considering potential shifts in catastrophe losses and insurance pricing conditions. The article highlights that the ongoing balance between operating strength and valuation will be critical for Travelers' future narrative.